Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease. The study ...

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The treatment consisted of two cycles of immunotherapy before ...

Biohaven’s phase 2 proof-of-concept study with BHV-7000 in major depressive disorder fails to meet its primary endpoint: New Haven, Connecticut Monday, December 29, 2025, 13:00 ...

HIGH POINT, N.C., (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today ...

Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine VERO BEACH, Fla., Dec. 17, 2025 ...

Denali Therapeutics (DNLI) announced the publication of results from the open-label Phase 1/2 clinical trial of its investigational, ...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...